Myasthenic Crisis After Recurrent COVID-19 Infection

Area of Science:

• Neurology
• Infectious Diseases
• Critical Care Medicine

Background:

• Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
• COVID-19 can trigger or exacerbate autoimmune conditions.
• Acute exacerbations of MG can lead to respiratory failure and crisis.

Purpose of the Study:

• To report on the management of a myasthenia gravis patient experiencing an acute crisis following two COVID-19 infections.
• To highlight the role of plasmapheresis in managing MG crisis during a pandemic.

Main Methods:

• Case report of a myasthenia gravis patient.
• Documentation of COVID-19 infection and subsequent myasthenic crisis.
• Administration and monitoring of plasmapheresis therapy.

Main Results:

• The patient survived two severe COVID-19 infections.
• Plasmapheresis was crucial for the patient's recovery from the acute myasthenic crisis.
• Successful management of a complex case involving autoimmune disease and viral illness.

Conclusions:

• Plasmapheresis remains a vital therapeutic option for managing severe myasthenic crises.
• COVID-19 can significantly worsen myasthenia gravis, necessitating prompt and aggressive treatment.
• This case underscores the importance of considering infectious triggers in autoimmune disease exacerbations.